Last reviewed · How we verify
Standard opioid plus methocarbamol
This combination product pairs an opioid analgesic with methocarbamol, a skeletal muscle relaxant, to provide pain relief and reduce muscle tension.
This combination product pairs an opioid analgesic with methocarbamol, a skeletal muscle relaxant, to provide pain relief and reduce muscle tension. Used for Acute musculoskeletal pain with muscle spasm.
At a glance
| Generic name | Standard opioid plus methocarbamol |
|---|---|
| Sponsor | Prisma Health-Upstate |
| Drug class | Opioid analgesic combination with skeletal muscle relaxant |
| Target | Mu-opioid receptor (opioid component); central nervous system polysynaptic pathways (methocarbamol component) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
The opioid component acts as a mu-opioid receptor agonist to reduce pain perception centrally, while methocarbamol is a central-acting muscle relaxant that depresses polysynaptic reflexes in the spinal cord and brainstem. Together, they provide complementary analgesic and muscle-relaxing effects for conditions involving both pain and muscle spasm.
Approved indications
- Acute musculoskeletal pain with muscle spasm
Common side effects
- Drowsiness/sedation
- Dizziness
- Nausea
- Constipation
- Lightheadedness
Key clinical trials
- Methocarbamol in Ventral and Inguinal HR (PHASE4)
- Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery (PHASE4)
- Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |